Figure 1 | Scientific Reports

Figure 1

From: Relationship between clinical phenotype and in vitro analysis of 13 NPT2c/SCL34A3 mutants

Figure 1

Expression of wild-type NPT2c in HEK cells. (a) NPT2c and GAPDH mRNA expression in HEK cells not transfected and transfected with wild-type NPT2c plasmid (0.5 μg of DNA and 1 μl of lipofectamine 2000 per well). Quantitative data represent 3 independent experiments. Statistical analysis was performed using a non-parametric Mann–Whitney test. *p < 0.05. (b) NPT2c immunofluorescence 48 h after transfection in HEK cells (0.5 μg of DNA and 1 μl of lipofectamine 2000 per well) localizes mainly at the plasmic membrane. (c) Phosphate accumulation with time in HEK cells transfected with WT NPT2c plasmid (0.5 μg of DNA and 1 μl of lipofectamine 2000 per well). Phosphate accumulation increases with time. Quantitative data represent 3 independent experiments. Statistical analysis was performed using a non-parametric Kruskall–Wallis test followed by Dunn’s multiple comparison post-hoc test. *p < 0.05. Simple line represents Kruskall–Wallis test and zig-zag lines represent Dunn’s multiple comparison post-hoc test. (d) Sodium-dependent phosphate uptake measured in HEK cells transfected with various amounts of WT NPT2c plasmid (0.01 μg, 0.1 µg and 0.5 µg per well). The more the amount of plasmid, the greater the phosphate uptake. Quantitative data represent 3 independent experiments. Statistical analysis was performed using a non-parametric Kruskall–Wallis test followed by Dunn’s multiple comparison post-hoc test. ***p < 0.001. Simple line represents Kruskall–Wallis test.

Back to article page